Investing.com’s stocks of the week

Investing.com -- AI news once again drove significant moves this week, with one name under pressure over its data center plans.

Here are Investing.com's stocks of the week:

Meta Platforms

Meta surged 11.3% on Monday and is on track to close up over 9% in the last week following its Meta Connect event, where the company detailed a series of AI breakthroughs.

Mizuho analyst Lloyd Walmsley reiterated an Outperform rating and $750 price target on the stock, saying the event more explicitly attached Muse AI as a killer app fused deeply into the company's hardware strategy, from AR glasses through to Muse Charm, a keychain-like device offering rapid access to the assistant.

Walmsley noted that Meta continues to pivot away from full VR toward a more AI-centric approach while still investing heavily in AR. He pointed to the product's rapid climb to the top of the iOS app store, strong download numbers and increasing promotion across Meta's own surfaces, and said the momentum should continue to drive "multiple expansion in Meta shares."

AMD

AMD jumped 10% on Monday and has gained 15.2% over the past week, crossing the $1 trillion market capitalization mark, currently standing at $1.028 trillion.

The company becomes the fourth US chipmaker to reach the milestone, joining Nvidia, Broadcom and Micron, as investors increase their bets on its growing presence in AI computing.

Akamai Technologies

Akamai rose 7.5% over the week after announcing a significantly expanded relationship with Anthropic worth $11.6 billion in contractual commitments over seven years. The stock opened sharply higher on Friday at $125.23 before pulling back to $115.50 as of 13:21 ET.

DA Davidson analyst Rudy Kessinger reiterated a Buy rating and $185 price target on Akamai, noting the deal follows a $1.8 billion, seven-year commitment Anthropic signed earlier this year and could be expanded by a further $9 billion over the period. He estimates EBIT margin on the $14.6 billion of CIS commitments signed year to date at around 30% at full revenue run-rate, adding that "future growth & EPS estimates will move substantially higher."

Moderna

Moderna rose 25.7% over the week, extending a rally that has run for more than a month on optimism around mRNA applications beyond COVID.

The gains follow Phase 3 data from the INTerpath-001 study, in which Moderna and Merck showed that combining the personalized cancer vaccine intismeran autogene with Keytruda delivered better outcomes than Keytruda alone in high-risk melanoma patients.

Oracle

Finally, Oracle was a large faller this week, down 8.2% after Bloomberg reported it issued a force majeure notice to the developer of its New Mexico data center, a unit of Blue Owl Capital, seeking to suspend payments should the facility miss its 2028 launch date.

The project has faced local opposition and regulatory setbacks.

Stifel analyst Brad Reback reiterated a Buy rating and $200 price target on Oracle, saying his understanding is that force majeure was not invoked, with the language instead added to lender documentation.

He noted Oracle has confirmed Project Jupiter remains on schedule, with construction around 26% complete and recent court rulings proving favorable on permitting issues.

Reback described the commentary as "a precautionary preservation of rights rather than a formal admission of a delay."

Original Article

You May Also Be Interested In

• BofA raises AMD target to $720, sees server CPU TAM tripling to $211B by 2030
• Bernstein sees downside risk to Apple's December quarter results
• SK Hynix’s Solidigm said to mull IPO that could value unit at $150B